Abstract: Embodiments of the present invention feature a dermal filler comprising a mixture of hyaluronic acid or a pharmaceutically acceptable salt thereof crosslinked with a degree of crosslinking (percent) ranging from 0.5 to 12 in an amount of 0.055 to 2.16% by weight, agarose in an amount between 0.15 to 3.5% agarose by weight and water, sodium chloride, non-gel therapeutic agents, and buffering agents to within a range of ten percent of isotonicity to create a G* value of between 50 and 400.
Abstract: Agent for treating retinal disease such as aged-related maculopathy comprising sodium/glucose cotransporter2 inhibitor (SGLT2 inhibitor) as an active ingredient.
Abstract: The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m? is 0 or 1, and wherein the total weight of mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition, and the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5.
Type:
Grant
Filed:
December 27, 2017
Date of Patent:
July 12, 2022
Assignee:
GREEN VALLEY (SHANGHAI) PHARMACEUTICAL CO., LTD. SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
Abstract: Provided are a ?-1,3-1,6-glucan powder having high solubility in water, a glucan-containing composition using the powder or the like, a method for producing the ?-1,3-1,6-glucan powder, an inclusion complex, a method for producing the inclusion complex, and a method for recovering a guest molecule. The ?-1,3-1,6-glucan powder has a saturation solubility in water at 25° C. of from 1.0 to 20.0 % by mass. The ?-1,3-1,6-glucan powder is such that in a particle size distribution of ?-1,3-1,6-glucans, determined by subjecting the ?-1,3-1,6-glucan powder to dynamic light scattering measurements, a particle size of a peak representing a largest volume fraction is in a range from 5 nm to 15 nm, and a volume fraction of a peak outside of the particle size range from 5 nm to 15 nm is 30 % or less of the volume fraction of the peak having the largest volume fraction.
Type:
Grant
Filed:
October 10, 2018
Date of Patent:
July 12, 2022
Assignees:
MITSUBISHI GAS CHEMICAL COMPANY, INC., KONAN GAKUEN
Abstract: The technology relates to the use of at least one macrocyclic lactone such as ivermectin or moxidectin to inhibit a coronavirus in a subject in order to treat, prevent or reduce the risk of infection by the coronavirus.
Type:
Grant
Filed:
March 15, 2021
Date of Patent:
June 21, 2022
Assignees:
Monash University, Melbourne Health
Inventors:
Kylie Michelle Wagstaff, Leon Caly, David Jans
Abstract: Provided are methods of treating a patient diagnosed with Fabry disease. Certain methods treat a pregnant patient with a therapeutically effective dose of migalastat or a salt thereof. Other methods treat a patient of childbearing potential with a therapeutically effective dose of migalastat or a salt thereof. Also described are the successful outcomes of pregnancies during which the pregnant patient is treated with migalastat.
Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.
Type:
Grant
Filed:
March 18, 2016
Date of Patent:
June 7, 2022
Assignees:
UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), HOSPICES CIVILS DE LYON, UNIVERSITE LAVAL
Inventors:
Manuel Rosa-Calatrava, Olivier Terrier, Julien Textoris, Guy Boivin, Mario Pizzorno
Abstract: Active components comprising lauric acid, or a lauric acid derivative, are utilized independently, or in combination, to provide new and useful compositions for bacteriostatic action against susceptible pathogens. The lauric acid derivative includes one or more of 12-aminododecanoic acid, 12-amino-1-dodecanoic acid methyl ester, sucrose monolaurate, 12-(7-nitrobenzofurazan-4-ylamino) dodecanoic acid, 4-nitrophenyl dodecanoate, 1-lauroyl-rac-glycerol, 3-oxo-N-(2-oxocyclohexyl) dodecanamide, butyl laurate, benzyl laurate, isoamyl laurate, monolaurin, isopropyl laurate, pentyl laurate, and hexyl laurate. A preparation includes combining the active component with lecithin, and after an initial processing phase, coating with chitosan or a carrier. Final compositions may be or may contain particles, such as nanoparticles. Final compositions, or formulations containing said final compositions, may be utilized internally, causing one or more membrane changes (e.g.
Type:
Grant
Filed:
August 13, 2018
Date of Patent:
June 7, 2022
Assignee:
Natureza Products, Inc.
Inventors:
Lynn S. James-Meyer, Gerald C. Coles, Tristan Alexander Cogan
Abstract: Provided herein are methods and systems and related compositions comprising an effective amount of one or more zwitterionic polysaccharide possibly in combination with one or more antibiotics, for treatment and/or prevention of sepsis or a condition associated thereto in an individual.
Type:
Grant
Filed:
June 10, 2016
Date of Patent:
May 17, 2022
Assignee:
California Institute of Technology
Inventors:
Sarkis K. Mazmanian, June L. Round, Yue Shen
Abstract: The invention provides a hydrogen sulfide releasing polymer compound having a polysaccharide backbone, wherein the compound has at least two substructures, and wherein said substructures are capable of releasing hydrogen sulfide by thiol activation as well as uses thereof. Additionally, a method of treatment and prevention of a skin condition, an ocular disease or osteoarthritis is provided.
Abstract: A process for the preparation of hydroxocobalamin hydrochloride. More particularly the present application relates to improved process for the preparation of Hydroxocobalamin hydrochloride. In addition the present application also relates to process for the preparation of novel amorphous form. This application particularly relates to a process for the industrial manufacture of hydroxocobalamin hydrochloride from cyanocobalamin. The present application also relates to the improvement in yield with better purity of Hydroxocobalamin hydrochloride.
Abstract: An object of the present invention is to provide a novel pharmaceutical agent for improving autism spectrum disorder, a pharmaceutical agent for improving a mental disease, or a supplement exerting an effect of improving social behaviors or developing sociality or an anti-anxiety and anti-stress effect or a functional food exerting such an effect. The present invention also provides a pharmaceutical agent for promoting the secretion of oxytocin and/or vasopressin in the brain. The above objects are achieved by a pharmaceutical agent for improving autism spectrum disorder, a pharmaceutical agent for improving a mental disease, or a supplement exerting an effect of improving social behaviors or developing sociality or an anti-anxiety and anti-stress effect or a functional food exerting such an effect, or a pharmaceutical agent for promoting the secretion of oxytocin and/or vasopressin, which comprises D-allulose as an active ingredient.
Abstract: A method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function. The method includes preparing a composition comprising Neoandrographolide as the active ingredient, and administering the composition to lower the blood sugar or blood lipid of a user, to prevent a decrease in liver function of a user, or to improve the renal function of a user. The Neoandrographolide is the only active ingredient in the composition.
Abstract: Flavonoids that are isolated from plant material of the genus Cecropia can be used to perturb G-protein coupled receptors in a mammalian cell. In some instances, one or more flavonoids may interact with one or more of the G-protein coupled receptors to transiently increase the concentration of cytosolic calcium. Administration of the isolated flavonoids can be used to treat hypertension, to protect the integrity of blood vessels and related conditions.
Type:
Grant
Filed:
October 28, 2020
Date of Patent:
April 19, 2022
Assignee:
Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia
Inventors:
Catherina C. Caballero-George, Andres Rivera Mondragon
Abstract: The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human. The human is administered a composition comprising 6?-sialyllactose (6?-SL) and/or lacto-N-tetraose (LNT).
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
April 19, 2022
Assignee:
Glycom A/S
Inventors:
Bruce McConnell, Louise Kristine Vigsnæs, Sami Damak, Norbert Sprenger, Francis Foata
Abstract: The present invention relates to 6?-sialyllactose and/or pharmaceutically acceptable salts thereof for use in the treatment of a disease selected from hearing loss and hearing loss—associated tinnitus.
Abstract: There is provided a pharmaceutical composition comprising cellulose obtained from algae, or a derivative of said cellulose, and an active pharmaceutical ingredient (e.g. from Type 2 and 4 BCS class), wherein the active pharmaceutical ingredient is in a predominantly amorphous form. Compositions of the invention find particularly utility as formulations comprising BCS Type 2 and 4 drugs, including NSAIDs or other drugs, that may be employed in the treatment of migraine or dysmenorrhea, as well as formulations comprising other poorly soluble active ingredients where rapid release in vivo is advantageous.
Abstract: Disclosed herein is a process for preparing nicotinamide riboside (NR) from an NR precursor and a phosphate-binding agent in a solvent. The reaction-derived mixture comprising NR may be further used without further processing in a variety of products, particularly in a cosmetic product.
Type:
Grant
Filed:
February 21, 2017
Date of Patent:
February 15, 2022
Assignees:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HIKARI LABORATORIES LTD.
Inventors:
Dmitri Gelman, Amani Zoabi, Assaf Zeira, Raed Abu-Reziq